ITC, one of India's largest diversified conglomerates, has confirmed it is developing a nasal spray for COVID-19 prevention. The company has initiated clinical trials with required ethics committee approvals and registration at India's Clinical Trial Registry (CTRI). The spray targets the virus at its primary entry point—the nasal cavity itself.
This development comes as respiratory virus prevention continues to evolve beyond traditional vaccine approaches. The concept of blocking pathogens at their point of entry represents a growing area of scientific interest and could add a new layer to existing prevention strategies.
The short version:
- ITC has begun clinical trials for a nasal spray targeting COVID-19 prevention
- The spray is designed to block the virus at the nasal entry point
- Developed by ITC's Life Sciences and Technology Center in Bengaluru
- Plans to market under the Savlon brand pending regulatory approval
- Ethics committee approvals secured; registered with CTRI
How Nasal Sprays Target Virus Entry
Unlike vaccines, which train the immune system to recognize pathogens, or antiviral treatments, which combat established infection, nasal sprays aim to neutralize viruses before they establish a foothold. The nasal cavity serves as the primary replication site for respiratory viruses, making it a logical intervention point.
Researchers have explored this delivery method across multiple respiratory pathogens. Direct application allows higher local concentrations of active ingredients compared to systemic approaches. For COVID-19 specifically, blocking transmission at the nasal level could complement existing prevention strategies, particularly in high-exposure environments.
ITC's Development Process
ITC's Life Sciences and Technology Center (LSTC) in Bengaluru developed the spray formulation. This facility has been central to ITC's health and hygiene product expansion during the pandemic. The company previously launched several Savlon-branded hygiene products through these R&D teams.
Ethics committee approvals have been obtained, and the trial is registered at Clinical Trial Registry-India (CTRI). The company declined to specify trial locations, manufacturing plans, or marketing timelines. An ITC spokesperson cited ongoing trials as the reason for limited comment.
The spray would be marketed under the Savlon brand if regulatory approval is granted. Savlon already includes ITC's antiseptic and hygiene offerings, giving the company established distribution channels for consumer health products.
Our Analysis: What This Means for Prevention
Current COVID-19 defenses rely primarily on systemic interventions. Vaccines reduce severe disease, antivirals treat established infection, and hygiene measures prevent exposure. A topical nasal spray offering additional protection could serve different use cases.
High-risk individuals might benefit from an extra barrier. Close-contact settings could see reduced transmission with broad adoption. The spray's potential to work alongside existing hygiene measures—masking, ventilation, hand hygiene—makes it a complementary approach rather than a replacement.
However, the gap between laboratory promise and clinical reality is often wide. Many early-stage products fail to demonstrate efficacy when tested broadly. Safety profiles also require validation, especially for products intended for repeated use over time.
ITC's existing brand presence in hygiene products could accelerate distribution if approved. But regulatory agencies will carefully assess whether benefits outweigh any risks before granting approval.
Say you are a frequently traveling professional who cannot avoid crowded spaces. A nasal spray providing an additional barrier at the point where viruses first enter your body could complement your existing precautions. This is the user scenario these products aim to serve.
What to Watch Next
ITC's nasal spray represents an early-stage candidate in COVID-19 prevention. Clinical trial duration varies significantly, and approval timelines remain uncertain. Watch for trial completion announcements and published efficacy data.
Peer-reviewed results will provide clearer evidence than company statements or media reports. If trials show favorable outcomes, regulatory review would follow—typically adding months to the timeline.
Key takeaways
- ITC has started clinical trials for a nasal spray designed to block COVID-19 at entry
- The product was developed at ITC's Life Sciences and Technology Center in Bengaluru
- Plans to market under the Savlon brand after regulatory approval
- Trial data will determine effectiveness and safety before any market launch
- The spray could complement existing COVID-19 prevention measures if approved
Frequently asked questions
What is ITC?
ITC is a major diversified Indian conglomerate with businesses spanning consumer goods, hotels, packaging, and life sciences.
How would a nasal spray work against COVID-19?
The spray targets the virus at the nasal cavity, where respiratory viruses first establish infection, potentially neutralizing them before they replicate.
When might the ITC nasal spray be available?
No specific timeline exists. Clinical trials are underway, and regulatory approval would be required before marketing, typically taking months to years.
What brand would sell the spray?
Sources indicate marketing under ITC's Savlon brand, which already includes pandemic-era hygiene products like antiseptics and cleaning solutions.
Has the spray's effectiveness been proven?
Not yet. Clinical trials are testing both effectiveness and safety before any regulatory review or approval process.